Docetaxel

Where the papers sit

18 papers from the last 6 months study docetaxel directly · updated from PubMed 12 Oct 2026

• Prostate Cancer Triplet Therapy

  Darolutamide plus androgen deprivation therapy and docetaxel is becoming a leading triplet strategy for metastatic hormone-sensitive prostate cancer. Real-world studies increasingly test its effectiveness and safety against androgen receptor pathway inhibitors. Biomarker work links docetaxel response to testosterone exposure and PRR7-associated Wnt/β-catenin signaling. Micellar formulations and prodrug nanoassemblies aim to improve delivery, while the best patient-selection markers remain unsettled.

  8 papers · 44.4%

• Docetaxel Combinations and Toxicity

  Clinical work centers on docetaxel efficacy, safety, and combination use across lung, breast, and esophageal cancers. Ramucirumab combinations are being evaluated in advanced non-small-cell lung cancer, while peripheral edema remains a recurring toxicity requiring risk assessment. In HER2-positive breast cancer, docetaxel is compared with eribulin or paclitaxel alongside trastuzumab and pertuzumab. Laboratory findings that cuproptosis sensitizes breast cancer cells and clinical DCF studies in esophageal cancer broaden the treatment questions without a single prevailing strategy.

  6 papers · 33.3%

• Targeted Docetaxel Delivery

  Docetaxel delivery is moving from free drug toward targeted micelles, peptide-drug conjugates, and core-shell nanofibers. Folate targeting and iRGD modification seek higher tumor or brain exposure with less nonspecific toxicity. These systems repeatedly report improved biodistribution, cell killing, or antitumor activity in preclinical models. Docetaxel-induced immune activation also supports combining targeted delivery with CD40 agonism, although clinical translation remains open.

  4 papers · 22.2%